{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:23Z","timestamp":1794047423329,"version":"4.8.0"},"reference-count":54,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"5","license":[{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Neutralizing anti-factor VIII (FVIII) antibodies, known as FVIII inhibitors, represent a major drawback of replacement therapy in persons with congenital hemophilia A (PwHA), rendering further infusions of FVIII ineffective. FVIII inhibitors can also appear in non-hemophilic individuals causing acquired hemophilia A (AHA). The use of non-FVIII bypassing agents in cases of bleeds or surgery in inhibitor-positive patients is complicated by the lack of reliable biological monitoring and increased thrombotic risk. Imlifidase (IdeS) is an endopeptidase that degrades human immunoglobulin G (IgG); it was recently approved for hyperimmune patients undergoing renal transplants. Here we investigated the ability of IdeS to eliminate FVIII inhibitors in vitro and in a model of inhibitor-positive HA mice. IdeS cleaved anti-FVIII plasma IgG from PwHA and AHA patients, and hydrolyzed recombinant human anti-FVIII IgG independently from their subclass or specificity for the A2, A3, C1 or C2 domains of FVIII. In HA mice passively immunized with recombinant human anti-FVIII IgG, IdeS restored the hemostatic efficacy of FVIII, as evidenced by the correction of the bleeding tendency. Our results provide the proof of concept for the transient removal of FVIII inhibitors by IdeS, thereby opening a therapeutic window for efficient FVIII replacement therapy in inhibitor-positive patients.<\/jats:p>","DOI":"10.3324\/haematol.2022.281895","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T03:23:56Z","timestamp":1674098636000},"page":"1322-1334","source":"Crossref","is-referenced-by-count":11,"title":["The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A mice"],"prefix":"10.3324","volume":"108","author":[{"given":"Melissa","family":"Bou-Jaoudeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Delignat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Daventure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Astermark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"L\u00e9vesque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan D.","family":"Dimitrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Deligne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Proulle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Lacroix-Desmazes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,1,19]]},"reference":[{"key":"47422","doi-asserted-by":"crossref","unstructured":"Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A - safety, efficacy, and development of inhibitors. N Engl J Med. 1993; 328(7):453-459.","DOI":"10.1056\/NEJM199302183280701"},{"key":"47423","doi-asserted-by":"crossref","unstructured":"Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol. 2013; 4(1):59-72.","DOI":"10.1177\/2040620712464509"},{"key":"47424","doi-asserted-by":"crossref","unstructured":"Tiede A, Collins P, Knoebl P. International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica. 2020; 105(7):1791-1801.","DOI":"10.3324\/haematol.2019.230771"},{"key":"47425","doi-asserted-by":"crossref","unstructured":"Lloyd Jones M, Wight J, Paisley S, Knight C. Control of bleeding in patients with haemophilia A with inhibitors: a systematic review. Haemophilia. 2003; 9(4):464-520.","DOI":"10.1046\/j.1365-2516.2003.00782.x"},{"key":"47426","doi-asserted-by":"crossref","unstructured":"Shapiro AD, Mitchell IS, Nasr S. The future of bypassing agents for hemophilia with inhibitors in the era of novel agents. J Thromb Haemost. 2018; 16(12):2362-2374.","DOI":"10.1111\/jth.14296"},{"key":"47427","doi-asserted-by":"crossref","unstructured":"Baudo F, Collins P, Huth-K\u00fchne A. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood. 2012; 120(1):39-46.","DOI":"10.1182\/blood-2012-02-408930"},{"key":"47428","doi-asserted-by":"crossref","unstructured":"Borg JY, Guillet B, Le Cam-Duchez V. Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de l\u2019H\u00e9mophilie Acquise) registry. Haemophilia. 2013; 19(4):564-570.","DOI":"10.1111\/hae.12138"},{"key":"47429","doi-asserted-by":"crossref","unstructured":"Shima M, Hanabusa H, Taki M. Factor VIII\u2013mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med. 2016; 374(21):2044-2053.","DOI":"10.1056\/NEJMoa1511769"},{"key":"47430","doi-asserted-by":"crossref","unstructured":"Lenting PJ, Denis CV, Christophe OD. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?. Blood. 2017; 130(23):2463-2468.","DOI":"10.1182\/blood-2017-08-801662"},{"key":"47431","doi-asserted-by":"crossref","unstructured":"Callaghan MU, Negrier C, Paz-Priel I. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021; 137(16):2231-2242.","DOI":"10.1182\/blood.2020009217"},{"key":"47432","doi-asserted-by":"crossref","unstructured":"Collins PW, Liesner R, Makris M. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee. Haemophilia. 2018; 24(3):344-347.","DOI":"10.1111\/hae.13495"},{"key":"47433","doi-asserted-by":"crossref","unstructured":"Lillicrap D, Fijnvandraat K, Young G, Mancuso ME. Patients with hemophilia A and inhibitors: prevention and evolving treatment paradigms. Expert Rev Hematol. 2020; 13(4):313-321.","DOI":"10.1080\/17474086.2020.1739518"},{"key":"47434","doi-asserted-by":"crossref","unstructured":"Makris M, Iorio A, Lenting PJ. Emicizumab and thrombosis: The story so far. J Thromb Haemost. 2019; 17(8):1269-1272.","DOI":"10.1111\/jth.14556"},{"key":"47435","doi-asserted-by":"crossref","unstructured":"von Pawel-Rammingen U, Johansson BP, Bj\u00f6rck L. IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G. EMBO J. 2002; 21(7):1607-1615.","DOI":"10.1093\/emboj\/21.7.1607"},{"key":"47436","doi-asserted-by":"crossref","unstructured":"Vincents B, von Pawel-Rammingen U, Bj\u00f6rck L, Abrahamson M. Enzymatic characterization of the Streptococcal endopeptidase, IdeS, reveals that it is a cysteine protease with strict specificity for IgG cleavage due to exosite binding. Biochemistry. 2004; 43(49):15540-15549.","DOI":"10.1021\/bi048284d"},{"key":"47437","doi-asserted-by":"crossref","unstructured":"Agniswamy J, Lei B, Musser JM, Sun PD. Insight of host immune evasion mediated by two variants of group a Streptococcus Mac protein. J Biol Chem. 2004; 279(50):52789-52796.","DOI":"10.1074\/jbc.M410698200"},{"key":"47438","doi-asserted-by":"crossref","unstructured":"Al-Salama ZT. Imlifidase: first approval. Drugs. 2020; 80(17):1859-1864.","DOI":"10.1007\/s40265-020-01418-5"},{"key":"47439","doi-asserted-by":"crossref","unstructured":"Wang Y, Shi Q, Lv H. IgG-degrading enzyme of Streptococcus pyogenes (IdeS) prevents disease progression and facilitates improvement in a rabbit model of Guillain-Barr\u00e9 syndrome. Exp Neurol. 2017; 291:134-140.","DOI":"10.1016\/j.expneurol.2017.02.010"},{"key":"47440","doi-asserted-by":"crossref","unstructured":"Soveri I, M\u00f6lne J, Uhlin F. The IgG-degrading enzyme of Streptococcus pyogenes causes rapid clearance of anti-glomerular basement membrane antibodies in patients with refractory anti-glomerular basement membrane disease. Kidney Int. 2019; 96(5):1234-1238.","DOI":"10.1016\/j.kint.2019.06.019"},{"key":"47441","doi-asserted-by":"crossref","unstructured":"Montgomery RA, Loupy A, Segev DL. Antibody-mediated rejection: new approaches in prevention and management. Am J Transplant. 2018; 18(S3):3-17.","DOI":"10.1111\/ajt.14584"},{"key":"47442","doi-asserted-by":"crossref","unstructured":"Leborgne C, Barbon E, Alexander JM. IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies. Nat Med. 2020; 26(7):1096-1101.","DOI":"10.1038\/s41591-020-0911-7"},{"key":"47443","doi-asserted-by":"crossref","unstructured":"J\u00e4rnum S, Runstr\u00f6m A, Bockermann R. Enzymatic Inactivation of endogenous IgG by IdeS enhances therapeutic antibody efficacy. Mol Cancer Ther. 2017; 16(9):1887-1897.","DOI":"10.1158\/1535-7163.MCT-17-0108"},{"key":"47444","doi-asserted-by":"crossref","unstructured":"Astermark J, Berntorp E, White GC, Kroner BL. The Malm\u00f6 International Brother Study (MIBS): further support for genetic predisposition to inhibitor development. Haemophilia. 2001; 7(3):267-272.","DOI":"10.1046\/j.1365-2516.2001.00510.x"},{"key":"47445","doi-asserted-by":"crossref","unstructured":"van den Brink EN, Turenhout EAM, Bovenschen N. Multiple VH genes are used to assemble human antibodies directed toward the A3-C1 domains of factor VIII. Blood. 2001; 97(4):966-972.","DOI":"10.1182\/blood.V97.4.966"},{"key":"47446","doi-asserted-by":"crossref","unstructured":"Jacquemin M, Benhida A, Peerlinck K. A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor. Blood. 2000; 95(1):156-163.","DOI":"10.1182\/blood.V95.1.156.001k50_156_163"},{"key":"47447","doi-asserted-by":"crossref","unstructured":"Jacquemin MG, Desqueper BG, Benhida A. Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood. 1998; 92(2):496-506.","DOI":"10.1182\/blood.V92.2.496"},{"key":"47448","doi-asserted-by":"crossref","unstructured":"Verbruggen B, Novakova I, Wessels H. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost. 1995; 73(02):247-251.","DOI":"10.1055\/s-0038-1653759"},{"key":"47449","doi-asserted-by":"crossref","unstructured":"Bi L, Lawler AM, Antonarakis SE. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet. 1995; 10(1):119-121.","DOI":"10.1038\/ng0595-119"},{"key":"47450","doi-asserted-by":"crossref","unstructured":"Russick J, Delignat S, Milanov P. Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA. Haematologica. 2020; 105(4):1129-1137.","DOI":"10.3324\/haematol.2018.210583"},{"key":"47451","doi-asserted-by":"crossref","unstructured":"Hemker HC, Giesen P, Dieri RA. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003; 33(1):4-15.","DOI":"10.1159\/000071636"},{"key":"47452","doi-asserted-by":"crossref","unstructured":"Jaki T, Lawo J-P, Wolfsegger MJ. A formal comparison of different methods for establishing cut points to distinguish positive and negative samples in immunoassays. J Pharm Biomed Anal. 2011; 55(5):1148-1156.","DOI":"10.1016\/j.jpba.2011.04.006"},{"key":"47453","doi-asserted-by":"crossref","unstructured":"Winstedt L, J\u00e4rnum S, Nordahl EA. Complete removal of extracellular IgG antibodies in a randomized dose-escalation phase I study with the bacterial enzyme IdeS \u2013 a novel therapeutic opportunity. PLoS One. 2015; 10(7)","DOI":"10.1371\/journal.pone.0132011"},{"key":"47454","doi-asserted-by":"crossref","unstructured":"Whelan SFJ, Hofbauer CJ, Horling FM. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Blood. 2013; 121(6):1039-1048.","DOI":"10.1182\/blood-2012-07-444877"},{"key":"47455","doi-asserted-by":"crossref","unstructured":"Nandakumar KS, Johansson BP, Bj\u00f6rck L, Holmdahl R. Blocking of experimental arthritis by cleavage of IgG antibodies in vivo. Arthritis Rheum. 2007; 56(10):3253-3260.","DOI":"10.1002\/art.22930"},{"key":"47456","doi-asserted-by":"crossref","unstructured":"Johansson BP, Shannon O, Bj\u00f6rck L. IdeS: a bacterial proteolytic enzyme with therapeutic potential. PLoS One. 2008; 3(2):e1692.","DOI":"10.1371\/journal.pone.0001692"},{"key":"47457","doi-asserted-by":"crossref","unstructured":"Yang R, Otten MA, Hellmark T. Successful treatment of experimental glomerulonephritis with IdeS and EndoS, IgG-degrading streptococcal enzymes. Nephrol Dial Transplant. 2010; 25(8):2479-2486.","DOI":"10.1093\/ndt\/gfq115"},{"key":"47458","doi-asserted-by":"crossref","unstructured":"Kizlik-Masson C, Deveuve Q, Zhou Y. Cleavage of anti-PF4\/heparin IgG by a bacterial protease and potential benefit in heparin-induced thrombocytopenia. Blood. 2019; 133(22):2427-2435.","DOI":"10.1182\/blood.2019000437"},{"key":"47459","doi-asserted-by":"crossref","unstructured":"Jordan SC, Lorant T, Choi J. IgG endopeptidase in highly sensitized patients undergoing transplantation. N Engl J Med. 2017; 377(5):442-453.","DOI":"10.1056\/NEJMoa1612567"},{"key":"47460","doi-asserted-by":"crossref","unstructured":"Kjellman C, Maldonado AQ, Sj\u00f6holm K. Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients. Am J Transplant. 2021; 21(12):3907-3918.","DOI":"10.1111\/ajt.16754"},{"key":"47461","doi-asserted-by":"crossref","unstructured":"Padmanabhan A, Connelly-Smith L, Aqui N. Guidelines on the use of therapeutic apheresis in clinical practice \u2013 evidence-based approach from the writing committee of the American Society for Apheresis: the eighth special issue. J Clin Apher. 2019; 34(3):171-354.","DOI":"10.1002\/jca.21705"},{"key":"47462","doi-asserted-by":"crossref","unstructured":"Wolfe GI, Ward ES, de Haard H. IgG regulation through FcRn blocking: a novel mechanism for the treatment of myasthenia gravis. J Neurol Sci. 2021; 430:118074.","DOI":"10.1016\/j.jns.2021.118074"},{"key":"47463","doi-asserted-by":"crossref","unstructured":"Blumberg LJ, Humphries JE, Jones SD. Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex\u2013mediated immune responses. Sci Adv. 2019; 5(12)","DOI":"10.1126\/sciadv.aax9586"},{"key":"47464","unstructured":"Muntean A, Lucan M. Immunosuppression in kidney transplantation. Clujul Med. 2013; 86(3):177-180."},{"key":"47465","doi-asserted-by":"crossref","unstructured":"Collins P, Baudo F, Knoebl P. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood. 2012; 120(1):47-55.","DOI":"10.1182\/blood-2012-02-409185"},{"key":"47466","doi-asserted-by":"crossref","unstructured":"Lee DSW, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discov. 2021; 20(3):179-199.","DOI":"10.1038\/s41573-020-00092-2"},{"key":"47467","unstructured":"European Medicines Agency. Idefirix (imlifidase): EU summary of product characteristics. 2020. Publisher Full Text|"},{"key":"47468","doi-asserted-by":"crossref","unstructured":"Reipert BM, Ahmad RU, Turecek PL, Schwarz HP. Characterization of antibodies induced by human factor VIII in a murine knockout model of hemophilia A. Thromb Haemost. 2000; 84(5):826-832.","DOI":"10.1055\/s-0037-1614124"},{"key":"47469","doi-asserted-by":"crossref","unstructured":"Batsuli G, Deng W, Healey JF. High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors. Blood. 2016; 128(16):2055-2067.","DOI":"10.1182\/blood-2016-02-701805"},{"key":"47470","doi-asserted-by":"crossref","unstructured":"Gangadharan B, Ing M, Delignat S. The C1 and C2 domains of blood coagulation factor VIII mediate its endocytosis by dendritic cells. Haematologica. 2017; 102(2):271-281.","DOI":"10.3324\/haematol.2016.148502"},{"key":"47471","doi-asserted-by":"crossref","unstructured":"Bonnefoy A, Merlen C, Dub\u00e9 E. Predictive significance of anti-FVIII immunoglobulin patterns on bleeding phenotype and outcomes in acquired hemophilia A: Results from the Quebec Reference Center for Inhibitors. J Thromb Haemost. 2021; 19(12):2947-2956.","DOI":"10.1111\/jth.15515"},{"key":"47472","doi-asserted-by":"crossref","unstructured":"Jordan SC, Legendre C, Desai NM. Imlifidase desensitization in crossmatch-positive, highly sensitized kidney transplant recipients: results of an international phase 2 trial (Highdes). Transplantation. 2021; 105(8):1808-1817.","DOI":"10.1097\/TP.0000000000003496"},{"key":"47473","doi-asserted-by":"crossref","unstructured":"Adamkewicz JI, Chen DC, Paz-Priel I. Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays. Thromb Haemost. 2019; 119(07):1084-1093.","DOI":"10.1055\/s-0039-1688687"},{"key":"47474","doi-asserted-by":"crossref","unstructured":"Huang E, Maldonado AQ, Kjellman C, Jordan SC. Imlifidase for the treatment of anti-HLA antibody-mediated processes in kidney transplantation. Am J Transplant. 2022; 22(3):691-697.","DOI":"10.1111\/ajt.16828"},{"key":"47475","doi-asserted-by":"crossref","unstructured":"Jim\u00e9nez-Yuste V, Rodr\u00edguez-Merch\u00e1n EC, Matsushita T, Holme PA. Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery. Haemophilia. 2021; 27(4):519-530.","DOI":"10.1111\/hae.14322"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281895\/75211","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281895\/75568","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10938\/75211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:03:13Z","timestamp":1794045793000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.281895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,19]]},"references-count":54,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.281895","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,19]]}}}